The carcinogenic potential of tacrolimus ointment beyond immune suppression: a hypothesis creating case report
<p>Abstract</p> <p>Background</p> <p>Since tacrolimus ointment was approved by the U.S. Food and Drug Administration (FDA) as a promising treatment for atopic dermatitis, it has been approved in more than 30 additional countries, including numerous European Union member...
Main Authors: | Vetter Claudia S, Houben Roland, Becker Jürgen C, Bröcker Eva B |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2006-01-01
|
Series: | BMC Cancer |
Online Access: | http://www.biomedcentral.com/1471-2407/6/7 |
Similar Items
-
Tacrolimus ointment in the management of atopic dermatitis
by: Antonello Baldo, et al.
Published: (2009-01-01) -
Tacrolimus ointment in the treatment of atopic hand eczema
by: Shri Joseph, et al.
Published: (2006-01-01) -
Effectiveness of tacrolimus ointment for dupilumab‐resistant facial erythema
by: Takeshi Fukumoto, et al.
Published: (2022-12-01) -
Nail lichen planus successfully treated with tacrolimus ointment
by: Chun-Wei Lu
Published: (2016-09-01) -
Efficacy of tacrolimus ointment for vitiligo and its effect on T cell levels
by: Su-fen CAI, et al.
Published: (2019-06-01)